Protocol for systematic review and meta-analysis of the evidence linking hippocampal neurogenesis to the effects of antidepressants on mood and behaviour

Juliana Aparecida Bolzan 1,2, Cilene Lino de Oliveira 1,2

ABSTRACT

Objective Studies in rodents associated the deficits of adult hippocampal neurogenesis with behavioural anomalies which may be reversed by antidepressant treatments. A previous systematic review (SR) and meta-analysis (MA) indicated a hierarchy within the proneurogenic effects of different antidepressants in naive rodents. The present review aims to evaluate a more comprehensive sample of studies investigating the links between the effects of different antidepressants and adult hippocampal neurogenesis.

Search strategy, screening annotation, data management Protocols were planned following Preferred Reporting Items for Systematic Review and Meta-Analysis Protocols guidelines. Searches in Embase, Medline, Scopus and Web of Science followed by screening with inclusion/exclusion criteria will provide relevant publications. First SR will summarise the effects of antidepressants on adult hippocampal neurogenesis on different laboratory rodents. Second SR will summarise the correlations between neurogenic and behavioural effects of antidepressants while the third will focus on cause–effect relationships between them. If feasible, data will be analysed by pairwise or network random-effect or multivariate MA to determine the direction, magnitude, significance and heterogeneity of the estimated effect sizes on global or subgroup levels. Funnel plotting, Egger regression, ‘trim and fill’ will be used to estimate the risk of publication bias. Quality assessment of the included publications will be performed by applying adapted CAMARADES, Syrcles’ risk of bias or CINeMA tools.

Reporting Find a preliminary version of this protocol at the Open Science Framework (https://osf.io/gmsvd/). Data extraction has already started. Results shall be published in a peer-reviewed journal. Due to the continuous production in the field, the implementation of a ‘living SR’ is intended.

INTRODUCTION

The consumption of antidepressant medications used in psychiatric treatments doubled according to the Organisation for Economic Co-operation and Development between the years 2000 and 2015. Despite a large number of patients under treatment, the mechanisms underlying therapeutic effects of antidepressants remain elusive. Behavioural studies indicate that the therapeutic effects of antidepressants depend on the reversal of neurochemical deficiencies. For example, earlier studies revealed that most antidepressants inhibit the reuptake of monoamines, promoting high extracellular concentrations in the central nervous system. Moreover, antagonism of monoaminergic transmission provoked sudden decay of the effectiveness of antidepressants in patients. Although durable, the relationships between monoamines, depression and antidepressants may not explain all aspects of antidepressant therapy. For example, the delay between the onset of treatment and remission of symptoms or the existence of depressions resistant to prototype antidepressants suggests there are more for depression than monoamines.
Animal models allow for discoveries generating hypothesis and theories on depression and antidepressant efficacy beyond monoamines. Neurogenic theory of depression gained more attention in the 2000s when a series of papers reported that chronic antidepressant treatment increased the number of newborn neurons in the hippocampus of adult rodents, suggesting a proneurogenic effect of the treatment. Stressful stimuli provoked hippocampal cell loss and behavioural sequelae prevented by chronic antidepressant treatment in rats indicating a positive correlation between proneurogenic and behavioural effects of the compounds. Furthermore, ablation of hippocampal neurogenesis reverted the effects of antidepressants on the behaviour of adult mice suggesting a cause–effect relationship between proneurogenic actions of antidepressants and their effects on behaviour. Altogether, these data engendered an explanation considering hippocampal neurogenesis as the underlying mechanism for the efficacy of antidepressants on treating mood and behavioural disorders.

Since the neurogenesis is a time-consuming process, the neurogenic theory offers a plausible explanation to delay between the onset of antidepressant treatment and the therapeutic effect. Neurogenic theory inspired a long series of studies aiming to understand details of the process which could provide a variety of new targets for the development of antidepressants. Over time the findings diverging of the earliest publications emerged indicating that some effects of antidepressants could be related to hippocampal neurogenesis while others would be unrelated to it. For example, the effects of chronic antidepressants on behavioural tests such as novelty suppressed feeding seem to correlate positively and depend on hippocampal neurogenesis. In contrast, the effects of antidepressants on the forced swimming test seem unrelated to it. A pioneer systematic review and meta-analysis (MA) of studies investigating effects of antidepressants in the hippocampus of adult laboratory rodents suggested that some compounds increased the neurogenesis while others did not. Depending on the type of the compound (fluoxetine, imipramine, venlafaxine, desvenlafaxine), laboratory species (rat or mice) and the type of molecular marker (BrdU, doublecortin, Ki-67), the magnitude of the effect size (ES) may vary from negligible to very large. The broad range of ES values indicates that actions of antidepressants may be more or less related or dependent on hippocampal neurogenesis.

To further explore the concept of the hierarchy of ES within different antidepressants, present work proposes to analyse the data of hippocampal neurogenesis with network MA. Network MA may enable indirect comparisons between ES. Additionally, the present protocol also plans to include studies of all times to perform a comprehensive systematic review and MA, which may help to overcome some of the limitations of the previous one. Although enough powered to evaluate ESs of different antidepressants on different species of laboratory rodents, boundaries of dates (5 years between 2013 and 2018) may have reduced the amount of data available to assess other sources of heterogeneity. Indeed, the information was insufficient to investigate the influence of relevant characteristics of the population such as sex, age and comorbidities (stressed, anxious and depressed phenotypes). Scarcity of relevant data also precluded the stratified analysis of the ESs of the antidepressants by doses, via of administration or efficacy in behavioural testing.

Considering there is a variety of primary studies investigating the theme, it seems not feasible to obtain all relevant information with a single systematic review. In a pilot analysis, at least three categories of studies investigating the links between hippocampal neurogenesis and antidepressants in laboratory rats were identified in the literature. For convenience, these categories were here named as 1-interventional, 2-correlational and 3-functional. Interventional category comprised those studies on the effects of the intervention (antidepressant) on the different markers of the hippocampal neurogenesis (neurogenic outcomes), for example. The correlational category included the studies on the effects of the antidepressant (intervention) on a behavioural testing (outcome) and different phases of the hippocampal neurogenesis (outcome), for instance. Functional studies were those making ablation of hippocampal neurogenesis (intervention), cotedrated or not with antidepressants, before behavioural testing (outcome), for example. There, three different systematic reviews (SR) were planned to summarise interventional (SR 1), correlational (SR 2) and functional (SR 3) studies. In summary, SR 1 will further extend and update previous MA while SR 2 and SR 3 will explore newer aspects of the subject.

The ‘neurogenic outcome’, appraised in SR 1 and SR 2, often means the combination of different outcomes (measures of stemness, proliferation, survival, maturation of newborn neurons). Besides, every behavioural testing, evaluated in SR 2 and SR 3, should provide a different behavioural outcome (eg, immobility time in the forced swimming test, latency to touch the food in the novelty suppressed feeding, so on). Since random-effects model assumes independence of the ESs, but often information from the primary studies did not allow to discard correlations between them, current protocol plan to apply multivariate MA to take non-independence of data into account.

**METHODS AND ANALYSIS**

**Overview of the SRs and MA**

The protocol and the manuscript follow Preferred Reporting Items for Systematic Review and Meta-Analysis Protocols statement and Syrcle’s formulay. However, approval by the ethics committee and the Helsinki Declaration does not apply. The plan of every SRs (SR 1, SR 2, SR 3) included the following steps: (1) research question; (2) choice of search strategy; (3) choice of bibliographic databases; (4) choice of inclusion and exclusion
criteria; (5) planning of data extraction and (6) planning of the MA (figure 1). SR 1, 2 and 3 aim to answer the following questions prepared using the PICO tool, respectively, (1) do different antidepressants increase hippocampal neurogenesis at different degrees in laboratory rodents? (2) are there correlations between behavioural and neurogenic effects of antidepressants in laboratory rodents? and (3) is there a causal link between behavioural and neurogenic effects of antidepressants in laboratory rodents?

In the three reviews, the population comprises laboratory rodents independent of species, strain, age, sex or comorbidities. Interventions and outcomes vary across SR, as follows. The SR 1 includes all studies investigating the effects of antidepressant treatment (intervention) on adult hippocampal neurogenesis (outcome), independent of the type of experimental design or association with behavioural testing. SR 2 will summarise the correlation between outcomes (hippocampal neurogenesis and behaviour). In those studies, the effects of antidepressant treatment (intervention) on adult hippocampal neurogenesis (outcome) and behaviour testing (outcome) are investigated in the same cohort of laboratory animals. Values of correlation will be extracted from primary studies, and when absent, calculated from the extracted data. SR 3 will condense those studies investigating the effects of ablating hippocampal neurogenesis (intervention) in laboratory rodent, with or without cotreatment with an antidepressant, evaluated in the selected behaviour testing (outcome).

Neurogenesis will be assessed through the measures of different molecular markers of neurogenesis in the adult hippocampus (BrdU, Ki-67, DCX), arbitrarily chosen according to previously published SRMA. The different stages of neurogenesis (figure 2) will be estimated by quantification of the following markers on the dentate gyrus of the hippocampus: (1) Nestin (expressed in stem cells), (2) BrdU (incorporated by proliferating cell) or Ki-67 (expressed in proliferating cells, or other markers such as Tbr2, Mash 1, PCNA), (3) DCX (expressed in immature neurons), (4) BrdU and NeuN (expressed in mature neurons or other markers of mature neurons such as Map-2, Fox-3, Prox-1) co-localised (indicating mature neurons incorporated BrdU and matured in the adulthood). Measurements of the markers may be using stereological or non-stereological methods. The behavioural outcomes depend on the type of behavioural test reported (e.g., time of immobility...
in forced swimming or tail-suspension test, latency to eat in the novelty suppressed feeding, so on). Data extract from each SR will be analysed separately. Analytical choices were made taken characteristics of the outcomes into account.

**Screening processes**

Screening of publications returned from the searches will occur in two rounds, the first one analysing title and abstract and second-round evaluating full text. The exclusion criteria are reviews, SRs, MAs, duplicates (all SR) and cotreatment (SR 1 and 2). The first round will exclude reviews, SRs, MAs, duplicates. The second round of screening will be required to identify cotreatments, exclusion criterion in SR 1 and 2, and apply inclusion criteria for all SRs.

All controlled studies will be included in SRs, regardless of randomisation, blinding or study design (figure 3). There will have no restriction on language or dates. Studies on adult rats or mice, regardless of sex, strain or stress background; studies with any route, dose and treatment schedule for drug administration; studies measuring any molecular markers in the dentate gyrus of the hippocampus (see figure 3) will be eligible. In these studies, interventions (antidepressants in SR 1 and 2; ablation of neurogenesis with or without co-treatment with an antidepressant, SR 3) will be compared with controls, that is, vehicle (SR 1 and 2) or sham ablation or the absence of the intervention (SR 3). Although studies with cotreatments will be included in SR 1 and 2, if the same study includes groups of animals treated with a single antidepressant and the respective control group, these groups will be included. One reviewer performed the screening process; a second reviewer will double check the screening. A third reviewer will solve discrepancies. Systematic reviewers will not be blinded to authors, date or journal of primary articles.

**Quality of study**

Quality of every publication will be estimated by the use of an adapted version of CAMARADES checklist22 (box 1) and risk of bias (RoB) Sycyle tools23 which assess,
Note: The quality of every study evaluated using the adapted CAMARADES checklist will vary from score 0 (minimum) to 10 (maximum). Every study may receive a score when reporting information required in the checklist anywhere in the text (title, abstract or body of the text). This version of the CAMARADES checklist was adapted using items 6 and 9 of ARRIVE V.2.0 guidelines. A score at item 9 may be obtained by reporting (ARRIVE item 9): ‘(1) What was done, how it was done, and what was used? (2) When and how often?; (3) Where (including detail of any acclimatisation periods)? (4) Why (provide a rationale for procedures)’. A score at item 10 may be obtained by reporting (ARRIVE item 6): ‘Clearly define all outcome measures assessed (eg, cell death, molecular markers, or behavioural changes)’. The quality of every study evaluated using SyrCy’s RoB tool will be performed by answering the ten signalling questions with ‘yes’, ‘unclear’ or ‘no’, which will be considered a ‘low’, ‘unclear’ and ‘high’ RoB, respectively. The quality using CINeMA tool considers the following domains: (1) within-study bias, (2) reporting bias, (3) indirectness, (4) imprecision, (5) heterogeneity and (6) incoherence. To each domain, three levels of judgement may be assigned: (1) no concerns, (2) some concerns or (3) major concerns. Judgements may be summarised to obtain four levels of confidence: (1) very low, (2) low, (3) moderate, or (4) high. Two independent reviewers will perform the quality assessment. A third reviewer will solve discrepancies.

Outcome extraction

For a qualitative and quantitative summary of the included studies, bibliographic information and data on the experimental design, population, intervention, comparison, and the qualitative and quantitative aspects of the outcomes will be extracted from every publication (Table 1). Qualitative data will be obtained from the text or tables. Quantitative data will be obtained from the text or tables of publications or using a digital ruler to extract them from the charts. When information is entirely unavailable in the publication, it may request directly by contact with the authors by e-mail of the corresponding author. In the absence of a response, within 30 days, the study will be excluded from the analysis. Two independent reviewers will extract data. A third reviewer will solve discrepancies. Every independent reviewer will input qualitative and quantitative data extracted from publications in an Excel sheet structured with a study per row and a variable per column. Agreement between reviewers will be assessed by using ‘comparing columns’ tool of the Excel (qualitative data) or by calculating Cohen Kappa index (quantitative data). Discrepancies above 20%, that is, a minimum 80% of concordance considered substantial, will be conciliated by the third reviewer.
the case of independent outcomes, randomisation and random allocation of antidepressants and all markers for neurogenesis. In a global estimate of ES will include all laboratory animals, normalised mean difference and expressed Hedges’ g will be calculated by using a pairwise analysis for each SR will be analysed independently. For every study included in each SR, an ES will be calculated by using the I². Since the random-effects model assumes independence of the ES, when the primary studies do not allow to discard correlations between outcomes, multivariate MA will be performed. Multivariate meta-analysis may be used to estimate ES and heterogeneity taking non-independence of data into account.17

Stratified MAs into the subgroups (1) population, (2) intervention and (3) outcome are planned (table 2). Meta-regressions and, if necessary stratified, will be performed to evaluate doses of the antidepressants. For comparisons between ES of different antidepressants, network MAs are planned for data of each SR.14 Funnel Plotting, Egger regression, trim and fill, and p curve will be used to estimate the risk of publication bias. Calculations will be performed using R Studio.28

Meta-analysis
Quantitative data extracted from publications (table 1) will be used in the MA. A similar protocol of the MA was previously published in the following studies.13 27 Data of each SR will be analysed independently. For every study included in each SR, an ES will be calculated by using a normalised mean difference and expressed Hedges’ g with the upper and lower 95% confidence limits. For each SR, a global estimate of ES will include all laboratory animals, all antidepressants and all markers for neurogenesis. In the case of independent outcomes, random-effect models will be used for the MAs, and heterogeneity will be assessed by using the I². Since the random-effects model assumes independence of the ES, when the primary studies do not allow to discard correlations between outcomes, multivariate MA will be performed. Multivariate meta-analysis may be used to estimate ES and heterogeneity taking non-independence of data into account.17

Stratified MAs into the subgroups (1) population, (2) intervention and (3) outcome are planned (table 2). Meta-regressions and, if necessary stratified, will be performed to evaluate doses of the antidepressants. For comparisons between ES of different antidepressants, network MAs are planned for data of each SR.14 Funnel Plotting, Egger regression, trim and fill, and p curve will be used to estimate the risk of publication bias. Calculations will be performed using R Studio.28

Prospects
The results of SR 1, SR 2 and SR 3 and the respective MA will be published independently in a peer-reviewed scientific journal. Implementation of a living SR (LSR) will be used to estimate ES and heterogeneity taking non-independence of data into account.17

Open access
This is an open access article distributed in accordance with the Creative Commons Attribution 4.0 Unported (CC BY 4.0) license, which permits others to copy, redistribute, remix, transform and build upon this work for any purpose, provided the original work is properly cited, a link to the licence is given, and indication of whether changes were made. See: https://creativecommons.org/licenses/by/4.0/

Open data
Supplementary are deposited at the Open Science Framework, access link: https://osf.io/taht/f/

ORCID iD
Juliana Aparecida Bolzan http://orcid.org/0000-0002-8537-943X

REFERENCES

Contributors CLdO: selected research theme; performed preliminary studies; wrote the preliminary protocol; wrote the manuscript; approved final version of the manuscript. JAB: performed preliminary studies; wrote the preliminary protocol; wrote the manuscript; approved the final version of the manuscript. Funding: This study was financed in part by the Coordenação de Aperfeiçoamento de Pessoal de Nível Superior—Brasil (CAPES)—Finance Code 001. JAB is a recipient of a fellowship from Conselho Nacional de Desenvolvimento Científico e Tecnológico, Brazil (131247/2019-0). Competing interests: Senior author (Clíene Lino de Oliveira) is an Associate Editor of BMJ Open Science. Other than that, no conflict of interest is declared. Open data: open data are available at (https://osf.io/ixb8u/).

Funding This study was financed in part by the Coordenação de Aperfeiçoamento de Pessoal de Nível Superior—Brasil (CAPES)—Finance Code 001. JAB is a recipient of a fellowship from Conselho Nacional de Desenvolvimento Científico e Tecnológico, Brazil (131247/2019-0).


